Clinical Trial Update: High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating high-dose or low-dose interferon alfa versus no further therapy after surgery for stage III melanoma; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Interferon Alfa (interferon alfa)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Melanoma (Skin) | Phase 3 | Status: UNKNOWN